Pembrolizumab plus enfortumab vedotin in urothelial cancer

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F24%3A10476022" target="_blank" >RIV/00669806:_____/24:10476022 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11140/24:10476022

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Pu_M4loJtK" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Pu_M4loJtK</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41585-024-00858-y" target="_blank" >10.1038/s41585-024-00858-y</a>

Result language

angličtina

Original language name

Pembrolizumab plus enfortumab vedotin in urothelial cancer

Original language description

The combination of pembrolizumab and enfortumab vedotin shows promise as a first-line therapy for advanced urothelial carcinoma. Enfortumab vedotin targets nectin-4, in turn enhancing T cell and natural killer cell activity, inhibiting immunosuppressive pathways and impeding tumour evasion. This synergy with pembrolizumab shows potential in enhancing immunotherapy for these patients.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Nature Reviews Urology

ISSN

1759-4812

e-ISSN

1759-4820

Volume of the periodical

21

Issue of the periodical within the volume

7

Country of publishing house

GB - UNITED KINGDOM

Number of pages

2

Pages from-to

387-388

UT code for WoS article

001148195700001

EID of the result in the Scopus database

2-s2.0-85183375616